BC
NBIX icon

Bridgefront Capital’s Neurocrine Biosciences NBIX Stock Holding History

Bridgefront Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,662
Closed -$537K – 717
2024
Q3 		$537K Buy
+4,662
New +$639K 0.21% 165
2024
Q2 		– Sell
-2,126
Closed -$293K – 606
2024
Q1 		$293K Sell
2,126
-327
-13% -$44.7K 0.22% 189
2023
Q4 		$323K Buy
+2,453
New +$282K 0.24% 154
2023
Q1 		– Sell
-2,894
Closed -$346K – 527
2022
Q4 		$346K Buy
+2,894
New +$339K 0.24% 174
2021
Q2 		– Sell
-2,170
Closed -$211K – 800
2021
Q1 		$211K Buy
+2,170
New +$228K 0.07% 565

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bridgefront Capital's NBIX Position: Q4 2024 in Review

Bridgefront Capital sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 4,662 shares — an estimated $537K sold.

Bridgefront Capital first reported a position in NBIX in Q1 2021 and held it in 5 quarters. The position peaked at $537K in Q3 2024. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Bridgefront Capital reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Bridgefront Capital sold 4,662 Neurocrine Biosciences shares in Q4 2024, an estimated $537K.
  • Bridgefront Capital first reported a position in Neurocrine Biosciences in Q1 2021 and held it in 5 quarters.
  • Bridgefront Capital's Neurocrine Biosciences position peaked at $537K in Q3 2024.
  • 600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Bridgefront Capital's 13F filing for Q4 2024, filed 14 Feb 2025.